Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease with Clinically Significant Fibrosis in Obese Patients with Type 2 Diabetes Mellitus - China, 2017-2024.

ABSTRACT:

What is already known about this topic?

Metabolic dysfunction-associated steatotic liver disease (MASLD) with clinically significant fibrosis substantially elevates the risk of liver-related complications and mortality. The American Diabetes Association consensus report specifically recommends systematic risk stratification for MASLD and hepatic fibrosis in patients with type 2 diabetes mellitus (T2DM), with particular emphasis on those presenting with obesity.

What is added by this report?

This multicenter study demonstrates that obese patients with T2DM exhibit a substantially elevated prevalence of MASLD with clinically significant fibrosis compared to their non-obese counterparts (26.7% vs. 8.4%). Furthermore, the prevalence escalates progressively with the accumu

SUBMITTER: Chen Y 

PROVIDER: S-EPMC12660146 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature